Nipah Vaccine Shows Promise in Early Human Trial, Lancet Study Reports

A recent Lancet study reveals encouraging safety and strong immune responses for a potential Nipah virus vaccine (HeV-sG-V) in a Phase 1 human trial. This offers crucial hope for preventing the deadly infection, particularly in regions like India, which faces recurrent outbreaks.

• Phase 1 trial found Nipah vaccine (HeV-sG-V) safe in healthy adults.
• Two doses generated strong, durable neutralising antibody responses.
• Single vaccine dose was insufficient for strong immunity.
• No serious adverse events reported during the US-based trial.
• Nipah virus is a WHO priority pathogen with high fatality rates.
• Indian experts hail findings as a 'milestone' in vaccine development.

Read the full story on Quick Digest.